Neuroanatomical correlates of dysglycemia in young children with type 1 diabetes mellitus

Short Title: Neuroanatomical effects of type 1 diabetes

Writing Committee: Matthew J. Marzelli\textsuperscript{1,2,*}, Paul K. Mazaika\textsuperscript{1,*}, Naama Barnea-Goraly\textsuperscript{1}, Tamara Hershey\textsuperscript{3}, Eva Tsalikian\textsuperscript{4}, William Tamborlane\textsuperscript{5}, Nelly Mauras\textsuperscript{6}, Neil H. White\textsuperscript{7}, Bruce Buckingham\textsuperscript{8}, Roy W. Beck\textsuperscript{9}, Katrina J. Ruedy\textsuperscript{9}, Craig Kollman\textsuperscript{9}, Peiyao Cheng\textsuperscript{9} and Allan L. Reiss\textsuperscript{1,8,10} for the Diabetes Research in Children Network (DirecNet)**

Affiliations: \textsuperscript{1}Center for Interdisciplinary Brain Sciences Research, Department of Psychiatry and Behavioral Sciences; \textsuperscript{2}Department of Bioengineering, Stanford University; \textsuperscript{3}Washington University in St. Louis, Departments of Psychiatry, Neurology and Radiology, \textsuperscript{4}University of Iowa, Pediatric Endocrinology, \textsuperscript{5}Yale University, Pediatric Endocrinology, \textsuperscript{6}Nemours Children’s Clinic, Pediatric Endocrinology, \textsuperscript{7}Washington University in St. Louis, Department of Pediatrics, \textsuperscript{8}Department of Pediatrics Stanford University, \textsuperscript{9}Jaeb Center for Health Research; \textsuperscript{10}Department of Radiology, Stanford University. *Co-lead authors **A full listing of the members of the study group is included in the acknowledgements

Corresponding author: Katrina J. Ruedy, MSPH. Jaeb Center for Health Research, 15310 Amberly Drive Suite 350, Tampa, FL 33647. Phone: 813-975-8690; Fax: 888-795-2858; e-mail: direcnet@jaeb.org

Word Count: 3995 (Abstract: 200)

Number of Tables/Figures: 4/3
Abstract

Studies of brain structure in type 1 diabetes mellitus (T1D) describe widespread neuroanatomical differences related to exposure to glycemic dysregulation in adults and adolescents. In this study, we investigate the neuroanatomical correlates of dysglycemia in very young children with early-onset T1D. Structural magnetic resonance images of the brain were acquired in 142 children with T1D and 68 age-matched controls (mean age: 7.0 ± 1.7 years) on six identical scanners. Whole-brain volumetric analyses were conducted using voxel-based morphometry to detect regional differences between groups and to investigate correlations between regional brain volumes and measures of glycemic exposure (including data from Continuous Glucose Monitoring). Relative to controls, the T1D group displayed decreased gray matter volume (GMV) in bilateral occipital and cerebellar regions ($p<0.001$) and increased GMV in the left inferior prefrontal, insula, and temporal pole regions ($p=0.002$). Within the T1D group, hyperglycemic exposure was associated with decreased GMV in medial frontal and temporal-occipital regions and increased GMV in lateral prefrontal regions. Cognitive correlations of IQ to GMV were found in cerebellar-occipital regions and medial prefrontal cortex for controls, as expected, but not for the T1D group. Thus, early onset T1D affects regions of the brain that are associated with typical cognitive development.
Introduction

Glucose dysregulation in Type 1 diabetes mellitus (T1D) can result in physiological complications such as neuropathies (1) and has also been linked to an increased risk for cognitive deficits and psychological dysfunction (2; 3). Neuroanatomical insult from dysglycemia may be particularly consequential in early childhood, which is a period of dynamic brain development that includes rapid myelination of neurons as well as maturation, modification, and pruning of synapses (4). While the effects of metabolic perturbations in T1D on central nervous system (CNS) structure are not fully understood, neuronal damage is generally believed to be a consequence of both hyper- and hypoglycemic states. More specifically, non-enzymatic glycation of neural tissue is believed to lead to increased oxidative stress during hyperglycemia (5), and ultimately neurodegradation, while cell death may be instigated through deficiencies in insulin-sensitive signaling pathways (6). Conversely, energy deprivation during hypoglycemia may abet defective apoptotic processes, spur reactive gliosis, or lead to cellular necrosis via excitotoxicity of glutamate receptors (7; 8). Accordingly, an improved understanding of the relation between dysglycemia and brain development, especially in young children, is necessary to better inform medical treatment and ultimately improve clinical outcomes of individuals with T1D.

Previous investigations of T1D brain structure have shown increased rates of cerebral atrophy during the course of normal aging (9), with more pronounced effects observed in adults with early-onset diabetes (10). These findings suggest increased vulnerability of the younger brain to the disease. However, differences in total gray matter volume (GMV) and total white matter volume (WMV) relative to controls have only been observed in middle age or older adults (mean
More fine-grain analyses using voxel-based morphometry (VBM) in adults with T1D relative to controls have detected smaller regional GMV in frontal, temporal, and parieto-occipital regions (12), areas which are responsible for language processing, executive function, and cognition. Neuroanatomical variations in adult T1D also have been linked to severe hypoglycemia exposure, lifetime hemoglobin A1C (HbA1C), disease duration, and severity of microangiopathy (12; 13).

Using cross-sectional and longitudinal analyses in older children and adolescents with T1D (mean age ~12.6 years), our colleagues at Washington University (14-16) and Stanford University (17) observed significant correlations between neuroanatomical changes in occipital, temporal, frontal, and hippocampal regions and either greater exposure to hyperglycemia (as evidenced by lifetime weighted average HbA1C) or severe hypoglycemic episodes. However, some of the brain-glycemia associations observed in these studies were contradictory to those reported in adults (12), a phenomenon that may be due to developmentally specific responses to glycemic insults or to the heterogeneity of glycemic exposure in the disease.

The current study was designed to determine if T1D in very young children (age range 4.0 to 10.0 years) is associated with significant changes in GMV or WMV relative to age- and sex-matched non-diabetic controls. We also sought to determine if such neuroanatomical variations within the T1D group were correlated with measures of glycemic exposure (e.g., HbA1C or glucose levels measured with continuous glucose monitors [CGM]) or with cognitive function. We hypothesized that rapidly developing brain regions are especially vulnerable to deviation
from a euglycemic state and that this vulnerability would be reflected in regional differences in gray and white matter volume in young children with T1D.
Research Design and Methods

Recruitment and Exclusion Criteria

Children between 4.0 and 10.0 years of age were recruited for this study at five clinical centers in the Diabetes Research in Children Network (DirecNet) consortium (Nemours Children’s Clinic, Stanford University, University of Iowa, Washington University in St. Louis, Yale University, and the Jaeb Center for Health Research). The Institutional Review Board at each participating center approved the study protocol. Informed written consent was obtained from the parent or legal guardian of all participants, and verbal assent was obtained from study participants as per local guidelines. Eligibility criteria for the T1D participants included age of onset of T1D ≥ 6 months of age, positive islet cell autoantibody testing [GAD65, ICA512, mIAA] if onset was < 12 months of age, and use of insulin for at least one month. Requirements for non-diabetic controls included HbA1c < 6.0% (42 mmol/mol), fasting glucose < 110 mg/dL, and no history of abnormal glycemic control. Sibling controls of T1D participants were considered for inclusion in the control group if they had negative antibody testing within the prior year. Exclusions for both groups included genetic or mental disorders that could impair neurological development, history of intellectual disability or significant learning disabilities, psychiatric treatment, premature birth (< 34 weeks gestation), low birth weight (< 2000g), and MRI contraindications (e.g., metal implants).

Participants

Of 214 participants for whom an MRI scan was obtained, four were excluded due to poor image quality. Imaging data for 142 T1D subjects (mean age: 7.0 ± 1.7 years; 66 female, 76 male) and 68 control subjects (mean age: 7.0 ± 1.8 years; 33 female, 35 male) were included in the analyses.
Table 1 provides further description of the cohort, which includes average T1D onset age of 4.1 ±1.9 years with an average T1D duration of 2.9 ±2.0 years.

**Cognitive Testing**

Trained examiners collected data on intelligence quotients (IQ) using the age-appropriate Wechsler Preschool and Primary Scales of Intelligence or Wechsler Intelligence Scale for Children IV, or the Wechsler Adult Scale of Intelligence test for parents (18-20). Cognitive results for full-scale IQ (FSIQ) were converted to normalized z-scores (Table 1).

**Diabetic Exposure and Continuous Glucose Monitoring**

Within the T1D group, a hyperglycemic index was determined based on all available HbA$_1C$ values since diagnosis and up to the time of participation in this study by computing the area under the curve above 6.0% (HbA$_1C$AUC$_{6\%}$) according to the trapezoid rule (additional glycemic measures are shown in Table 1). A CGM device was used to obtain a minimum of 72 hours of glycemic data in a six-day period (with at least 24 hours of overnight data) and within 90 days prior to the MRI. Data within 28 days post MRI were included if a subject had less than 30 hours of pre-MRI CGM data. CGM measures included mean glucose value, coefficient of variation (CV), standard deviation (SD), and mean amplitude of glycemic excursions (MAGE) (21).

**MRI Preparation**

All study participants were introduced to a mock MRI environment to desensitize them to the sights and sounds they would encounter during the scan. Research staff was trained to identify and correct behaviors that might result in motion-related artifacts in the images.
**MR Data Acquisition**

Unsedated MR imaging was performed on Siemens 3T Tim Trio whole body MR systems using a standard 12-channel head coil. All six imaging sites had the same scanner hardware, and an identical imaging protocol was uploaded to every scanner. Sagittal T1 images of the brain were acquired (right to left) using a magnetization prepared rapid gradient echo (MP-RAGE) pulse sequence with the following parameters: repetition time [TR]=2300 ms, echo time [TE]=2.98 ms, inversion time [TI]=900 ms, flip angle=9°, slice thickness = 1 mm, FOV = 25.6 cm x 24 cm, 160 slices, matrix = 256x256, voxel size =1.0x1.0x1.0 mm, and duration = 4:54 minutes. By default, two MP-RAGE acquisitions were obtained for all participants to increase the probability that at least one scan would be collected with minimal head motion (22). A second MRI session was performed on a separate day if the initial scan could not be successfully completed or if image quality was deemed unacceptable after the first attempt. Additionally, for diabetic subjects, a finger stick blood glucose level was required to be between 70 and 300 mg/dL within 60 minutes prior to all scan sessions.

**Voxel-Based Morphometry**

All images were visually inspected to identify the highest quality MP-RAGE scan for each participant. Participants without at least one high quality scan (2 T1D, 2 control) were eliminated from further analysis. Voxel-wise volumetric analysis of MP-RAGE data was performed on the remaining 210 scans by well-established methods using Statistical Parametric Mapping software (SPM8, Wellcome Department of Imaging Neuroscience, University College London, [http://www.fil.ion.ucl.ac.uk/spm](http://www.fil.ion.ucl.ac.uk/spm)) in MATLAB (The MathWorks, Natick, MA). Each image
volume was manually aligned onto the axis of anterior-posterior commissures (23). Data were corrected for magnetic field inhomogeneity and subsequently segmented into gray matter (GM), white matter (WM), and cerebrospinal fluid volumes based on a priori adult tissue probability maps and spatially constrained tissue classification based on neighboring voxels (24; 25). High-dimensional, inter-subject registration was then performed by generating a cohort-specific template using the DARTEL toolbox in SPM (26). Images were warped and modulated into Montreal Neurological Institute (MNI) space for reporting of results, down-sampled to 1.5×1.5×1.5mm voxels, and spatially smoothed using a 6mm full-width at half-maximum (FWHM) Gaussian smoothing kernel.

**Whole-Brain Between-Group Analysis**

Regional differences in brain morphology between T1D and control subjects were analyzed based on the general linear model (GLM) using voxel-wise two-sample t-tests to create a t-statistic parametric map of the whole brain. Analyses of GMV and WMV were independently restricted to voxels with a mean tissue class probability>0.15. Statistical inference was evaluated using the VBM toolbox (Christian Gaser, University of Jena, http://dbm.neuro.uni-jena.de/vbm/) to threshold the voxel-level t-statistics at a height corresponding to \( p<0.05 \) (uncorrected) and at a cluster extent threshold of \( p<0.05 \) (corrected for family-wise error [FWE]) while accounting for non-stationary smoothness of the data (27).

**Whole-Brain Regression Analysis**

Within each group (T1D and controls analyzed separately), voxel-wise multiple linear regression was used to examine whole-brain correlations between imaging data and glycemic or cognitive
variables after first accounting for the effects of total GMV (or WMV), age, and sex. For age-related clinical variables (e.g. age of onset, disease duration, and HbA1C AUC_6%), an alternative two-step analysis was used to separate the effects of age and exposure. First, VBM was applied using only GMV (or WMV) as a covariate, and the mean value of each significant cluster was extracted for each subject for a region-of-interest (ROI) analysis. Then, a hierarchical linear regression analysis (IBM SPSS Statistics v19) removed the effect of total GMV from the ROI, and analyzed the independent contributions of age, sex, and the clinical variable to the residual volumes. To investigate differences in cognitive correlations between groups, an ANOVA of mean cluster volume by GMV, age, sex, group, FSIQ, and Group x FSIQ interaction was performed in SPSS to test for significant interaction effects. In defining the analyses performed in this study, pre-existing hypotheses of critical factors in diabetes were used to identify clinical variables of interest, and child FSIQ was adjusted for parent IQ. Accordingly, the analyses are parallel tests of hypotheses, rather than exploratory analyses, and so further corrections for multiple comparisons (beyond the employed FWE cluster extent correction for imaging data) were not applied.

**Multisite Effects**

Identical scanners were used at every site and continued calibrations were performed to confirm the repeatability of measurements across sites. The same two adult human phantoms were scanned on every machine prior to study start and again annually for two years. A standard plastic phantom (American College of Radiology [ACR]; available at each site) was also scanned at each site quarterly to monitor for possible temporal variations in scan quality. Additional human and/or ACR data were acquired both before and after hardware or software
upgrades. We observed less than 0.5% variation in geometric size across sites, which was not significantly larger than the observed intrasite variation of 0.4%. The possibility of multi-site effects affecting the VBM statistical results were investigated using a full factorial design with fixed factors for diagnosis (2 levels: T1D, control) and scanner (6 levels: scanners 1-6), while covarying for the effects of total GMV (or WMV), age, and sex (28). F-tests showed a significant main effect of scanner in the GM in left anterolateral inferior temporal gyrus (ITG) and fusiform gyrus (-22, 10, -40 [x,y,z]; \( F=6.62, p=0.01, k=4826 \)), and a significant diagnosis × scanner interaction bilaterally in central and posterior WM (-36, -45, 33 [x,y,z]; \( F=5.47, p=0.002, k=5947 \)). Consequently, all potential diabetes results in these regions were analyzed using scanner as a covariate in the analyses. To further examine the effect of multiple scanners, between group-analyses of T1D versus controls were performed using a two-sample t-test (also covaried for total GMV [or WMV], age, and sex) both with and without the inclusion of scanner as a nuisance variable (by coding \( n \) scanners into \( n-1 \) dichotomous variables). It was determined that the inclusion of scanner as a covariate had negligible impact on the results.

**Results**

**Total Brain Volumes**

No significant differences were detected between T1D and controls in total GMV, WMV, or GMV+WMV, adjusted for age and sex (Table 1).

**Between-Group Differences**

Voxel-wise whole brain volumetric analysis revealed significantly decreased GMV in T1D subjects relative to controls bilaterally in cerebellum, precuneus, cuneus, calcarine, lingual gyrus,
and fusiform gyrus (Table 2, Figure 1). Conversely, increased GMV was observed in T1D subjects relative to controls in left lateral prefrontal cortices (middle frontal gyrus [MFG], inferior frontal gyrus [IFG], and superior frontal gyrus [SFG]), extending into the superior temporal gyrus (STG), middle temporal gyrus (MTG), and insula. Gray matter volume was 3.6% less for T1D relative to controls averaged over the posterior cluster, and 4.2% greater in the left lateral frontal cluster. These effect sizes are much larger than the calibrated differences across scanners (0.5%), and both clusters remained significant after accounting for the effect of multiple scanners. No significant regional WMV differences were observed between T1D and controls, both with and without accounting for the effects of multiple scanners.

**Glycemic-Structural Correlations**

Within the T1D group, the ROI analysis of clinical measures of glycemic exposure (Figure 2) showed that GMV was negatively correlated with HbA$_1C$AUC$_{6\%}$ in bilateral lingual gyrus, fusiform gyrus, right parahippocampal gyrus, and cerebellum ($p<0.001$). Similarly, GMV was negatively correlated with duration of diabetes in the bilateral medial orbitofrontal and rectal gyri and the anterior cingulate ($p=0.001$), and WMV was negatively correlated with disease duration in the left anterior frontal lobe ($p<0.001$). Additionally, HbA$_{1C}$ at diagnosis (HbA$_{1C}$D$_X$, $n=116$) was positively correlated with GMV in a lateral frontal cluster including the left middle and inferior prefrontal cortex (MFG, IFG), lateral orbitofrontal gyrus, insula, and extending into the anterior STG and MTG ($p=0.01$). A similar trend ($p=0.05$) was observed for a cluster in the right prefrontal cortex (Table 2).
Voxel-wise regression for the CGM measures showed that mean glucose was negatively correlated with GMV in a posterior region including right cerebellum, lingual, fusiform, and inferior temporal regions ($p=0.007$) (Figure 2). Conversely, mean glucose was positively correlated with GMV in the left inferior frontal, insula, and anterior STG regions ($p=0.03$). Measures of glucose variability, including CV, SD, and MAGE, did not show significant GMV correlations (SD and MAGE were corrected for mean blood glucose).

Spatial overlaps of between-group differences and within-group glycemic correlations for T1D were observed in several brain regions (Table 3). In the right cerebellum, GMV was smaller in T1D than controls and reduced GMV was associated with higher HbA$_1C$AUC$_6\%$ and higher mean BG. Conversely, in the left insula, GMV was larger in T1D than controls and increased GMV was associated with higher mean BG and HbA$_1C$D$_X$. Thus, correlations of regional brain volumes with measures of glycemic exposure in the T1D group were consistent with observed volumetric differences between T1D and controls in these conjunction regions.

**Cognitive-Structural Correlations**

Within the control group, whole brain voxel-wise regression analysis revealed that IQ was significantly positively correlated with GMV in a large medial frontal cluster including bilateral anterior cingulate, superior medial frontal gyrus, and medial orbitofrontal gyrus, and in a posterior cluster including bilateral superior cerebellum and inferior occipital regions (Table 2, Figure 3). A similar whole brain analysis for the T1D group did not detect any significant correlations of regional GM with IQ. An ROI analysis within each cluster derived from the control group revealed a significant interaction of $Group \times FSIQ$ (frontal cluster, $p<0.001$;
posterior cluster, $p<0.006$), indicating that children with T1D had atypical trajectories of GM development in these regions.

**Regions with both Glycemic-Structural and Cognitive-Structural effects**

Conjunction analyses were performed on the brain regions associated with both glycemic exposure in T1D and FSIQ in controls. Regions were defined by the spatial overlaps of glycemic-structural clusters and cognitive-structural clusters (Table 4, Figure 3). In the medial orbitofrontal and anterior cingulate conjunction, GMV was positively correlated with FSIQ for both controls ($p=0.007$) and T1D ($p=0.014$), while the $Group \times FSIQ$ interaction was not significant ($p=0.13$). In the right fusiform, lingual gyrus, and cerebellum, FSIQ was positively correlated with GMV in controls ($p<0.001$) but not T1D, and the $Group \times FSIQ$ interaction was significant ($p<0.001$). Similarly, in the bilateral cerebellum, right lingual and right cuneus conjunction region, FSIQ was positively correlated with GMV only in controls ($p<0.005$), and the $Group \times FSIQ$ interaction was significant ($p<0.025$). Thus, T1D is associated with decreased GMV, and a decrease in GMV-IQ correlations, in the same cerebellar-occipital regions where increased GMV is associated with higher IQ in controls. No significant IQ correlations were found in regions that showed hyperglycemic-associated increases in GMV in T1D.

**Glycemic Measures at Time of MRI**

Blood glucose measurements for T1D subjects immediately prior to the scan session were not significantly correlated with regional brain volumes (mean glucose: $165 \pm 64$ mg/dL), nor were mean glucose measurements across the scan session (mean glucose: $183 \pm 64$ mg/dL) and absolute changes in blood glucose at the end of the MRI (mean change: $56 \pm 44$ mg/dL).
Discussion

The current study is the first to investigate the neuroanatomical effects of glycemic dysregulation in a large cohort of very young children with T1D (mean age: 7.0 years; mean duration: 2.9 years). We report differences in regional brain volumes in young children with T1D relative to controls and in association with glycemic exposure. The results were concentrated in three different brain regions that are discussed below.

Occipital Regions and Cerebellum

Hyperglycemia was found to be associated with smaller GMV in bilateral occipital-temporal regions and cerebellum using multiple methods of analysis. We observed significantly smaller GMV for T1D in a between-group analysis for these regions (Figure 1), as well as a negative correlation of GMV with increased HbA$_{1C}$AUC$_{6\%}$ exposure and higher mean glucose levels (Figure 2). The occipital lobe findings in our study are consistent with reductions in occipital GMV and WMV that have been linked to hyperglycemia exposure in older children and adolescents with T1D, to thinner occipital cortex in adults with T1D, and to the presence of microangiopathy (12; 13; 16; 29). Results indicating a negative correlation of GMV with HbA$_{1C}$AUC$_{6\%}$ exposure in the fusiform and lingual gyri are located inferior to similar correlations in the cuneus and posterior cingulate reported by Musen et al. (12); however, their study was in adults and included patients with long durations of diabetes and widely varying age of diabetes onset.
The between-group and hyperglycemic results located in the cerebellum have not been previously reported. The cerebellum is a region of active development during childhood, both in absolute volume and volume relative to the cerebrum (30). The superior-posterior cerebellum is known to be involved in many tasks including working memory, executive function, and motor control (31; 32) and the volume of the superior cerebellum has been found to be positively correlated with IQ (33). For control subjects, we found that IQ was positively correlated with regional GMV in superior cerebellum. However, T1D subjects did not show this correlation, and there was a significant group by region interaction for this region indicating that cerebellar development underlying general cognition is disturbed in children with T1D relative to controls.

**Medial Frontal Regions**

The duration of diabetes was negatively correlated with GMV in medial-frontal regions (Figure 2) consistent with the previously reported loss of GMV in this region for adults (12). Studies of normal brain development have shown that the frontal lobe, and particularly the medial frontal lobe, have rapid increases in GMV throughout early childhood, with frontal GMV cresting around age 11 (34). In addition, increased IQ has been associated with more rapid thickening along the bilateral superior/medial prefrontal cortex (35). For control subjects, we found this well-established result, that IQ was positively correlated with GMV along the medial superior frontal gyrus and the medial orbitofrontal gyrus. However, children with T1D did not show this correlation and, in fact, had significantly different IQ-GMV correlations than controls for this cluster. Hyperglycemia may affect GM growth since it has been associated with reduced insulin-like growth factors leading to deficiencies in neurotrophic growth factors and thus reduced dendritic arborization (36). Recent studies have also suggested that brain metabolites important
for osmotic regulation are significantly altered at acute hyperglycemic onset and that defective cell volume regulation due to increased oxidative stress may lead to neuronal loss (37; 38). Thus, these results indicate that early onset diabetes may interfere with the normal growth trajectory of GM in this frontal region.

White matter was negatively correlated with diabetes duration in the nearby left anterior frontal lobe. A recent study of changes in WM pathology in a rat model of diabetes found that abnormalities such as myelin loss were not present in early disease stages, but instead developed over time (39), suggesting that large-scale WMV variations might not yet be fully discernable in our young cohort. Previous diffusion tensor imaging studies in young children and adolescents (40; 41), as well as a similar companion study of our cohort (unpublished data), showed reduced diffusivity in multiple brain regions in subjects with T1D relative to controls, which may precede detectable WMV loss.

Left lateral frontal and insula regions

Using multiple analysis methods, hyperglycemia was associated with increased GMV in the left lateral prefrontal cortex, insular cortex, and anterior temporal lobe. These regions showed a significant between group difference in GMV for T1D greater than controls, and within the T1D cohort these regions showed positive correlations of GMV with HbA1C at diagnosis (HbA1CDX) and higher mean BG levels. Similar to the medial prefrontal region, the insula is also one of the fastest growing regions during childhood (34). While these regions are associated with executive function (42), interoceptive awareness (43), and auditory and language processing (44), we did not find cognitive correlations with FSIQ for these clusters. It is possible that the increase in
GMV in these regions may be due to a neuroinflammatory response to increased oxidative stress from the formation of advanced glycation end products during hyperglycemia exposure (45) or, more speculatively, may compensate for loss of GMV in the cerebellum and occipital regions.

Limitations

The current study is limited by several factors. First, the cross-sectional nature of this study limits conclusions about developmental changes that occur in brain growth due to T1D. Results from an ongoing longitudinal analysis may help to further clarify the neurodevelopmental growth of young children with T1D. Second, this study reports large, non-localized clusters because the algorithm parameters were set under the assumption that diabetes may cause weak, but widespread, effects. Future studies should try to better localize these brain regions. Finally, this study did not consider factors such as exposure to diabetic ketoacidosis and severe hypoglycemic events, or performance on measures assessing more specific cognitive and behavioral domains.

Summary

Neuroanatomical differences in the lateral frontal, medial frontal, occipital, and cerebellar brain regions were found to be associated with dysglycemia in young children with early-onset T1D relative to a well-matched healthy control group. Overlapping regional results were obtained for both between group studies and regressions within the T1D group for hyperglycemic variables. The medial prefrontal regions, insula, and cerebellum are known to be regions of rapid development in childhood and may be particularly vulnerable to glycemic effects from early onset of the disease. Control subjects had a significant positive correlation of IQ with GMV in the medial prefrontal lobe and cerebellum-occipital regions; these correlations were not present
in the diabetic group. Thus, these regions may be associated with the effect of early onset diabetes on cognitive function. Conversely, the only WMV effect was in the left anterior frontal lobe, perhaps due to the limited disease duration in this young cohort. A longitudinal analysis of this and other young pediatric cohorts will help better define the neuroanatomical profile and developmental trajectory of the T1D brain.
Acknowledgements

The authors thank the participants and their families as well as the clinical and imaging staff at all of the investigator sites. We also thank our external collaborators for use of their imaging facilities, including University of California at San Francisco, El Camino Hospital, and University of Florida & Shands Jacksonville. This research was supported by funding from Jaeb Center for Health Research and the NIH (DIRECNET U01 HD41890, HD41890-10, HD41906-10, HD41908-10, HD41915, HD41918, HD56526) and UL1 RR024992. B. Buckingham reports receiving sensors at a research discount from Medtronic. He also reports receiving payment for serving on membership board for Medtronic and Sanofi-Aventis and reports money paid to his institution for a pending Medtronic grant and NIH grant HD41908-10. T. Hershey reports receiving payment for consultancy for an NIH grant review, payment from Washington University as a faculty member, payment for work on the Scientific Advisory board for the Tourette Syndrome Association, and payment to her institution from NIH grant HD56526. She also reports money paid to her institution from the NIH for a pending grant and support for travel to meetings for the study from NIH grant HD56526. A. Reiss reports money paid to his institution from the NIH for a pending grant and NIH grant HD41908-10. He also reports money paid to his institution from the NIH grant HD41908 for travel to meetings for the study. N.H. White reports receiving payment for consultancy from Novo Nordisk and Daiichi Sankyo and payments to his institution from BistolMyers Squibb for a research grant and NIH grant HD56526. He also reports money paid to his institution from the NIH grant HD56526 for travel to meetings for the study. M. Marzelli, P. Mazaika, and N. Barnea-Goraly report payment to their institution from NIH grant HD41908-10. E. Tsalikian has received payment to her institution from NIH grant HD41915. W. Tamborlane has received payment to his institution
from NIH grant HD41906. N. Mauras has received payment to her institution from NIH grant HD41918. K. Ruedy, R. Beck, C. Kollman, and P. Cheng report payment to their institution from NIH grant HD41890-10.

M.M., P.M. and A.R., researched data, contributed to discussion, wrote manuscript, and reviewed/edited manuscript. N.B-G. T.H., E.T., W.T., N.M., N.W., B.B., R.B., K.R., C.K., and P.C. researched data, contributed to discussion, and reviewed/edited manuscript.

R.B. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The DirecNet Study Group:

**Clinical Centers:** (Personnel are listed as (PI) for Principal Investigator, (I) for co-Investigator and (C) for Coordinators.) **Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA:** Eva Tsalikian, MD (PI); Michael J. Tansey, MD (I); Julie Coffey, MSN (C); Joanne Cabbage (C); Sara Salamati (C); **Nemours Children’s Clinic, Jacksonville, FL:** Nelly Mauras, MD (PI); Larry A. Fox, MD (I); M. Allison Cato, PhD (I); Kim Englert, RN, BSN, CDE (C); Kaitlin Sikes, ARNP, MSN (C); Tina Ewen (C); **Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford, CA:** Bruce A. Buckingham, MD (PI); Darrell M. Wilson, MD (I); Tandy Aye, MD (I); Kimberly Caswell, ARNP (C);

**Department of Pediatrics, Yale University School of Medicine, New Haven, CT:** Stuart A. Weinzimer, MD (PI); William V. Tamborlane, MD (I); Amy Steffen, BS (C); Kate Weyman, MSN (C); Melinda Zgorski, BSN (C); **Washington University in St. Louis, St. Louis, MO:** Neil H. White, MD, CDE (PI); Ana Maria Arbelaez, MD, (I); Lucy Levendoski, PA-C (C); Angie Starnes, RN, BSN, CDE (C), Tamara Hershey, PhD (I); **Coordinating Center:** Jaeb Center for Health Research, Tampa, FL: Roy W. Beck, MD, PhD; Katrina J. Ruedy, MSPH;
Craig Kollman, PhD; Peiyao Cheng, MPH; Beth Stevens; **Image Coordinating Center**: Allan L. Reiss, MD; Naama Barnea-Goraly, MD; Matthew J. Marzelli, BS; Paul M. Mazaika, PhD;

**Cognitive Core**: Tamara Hershey, PhD; Colleen Considine; Aiden Bondurant; Michaela Cuneo; Emily Bihun; Sarah June Grafeman, PhD.
References

1. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D: Diabetic Neuropathies: A statement by the American Diabetes Association. *Diabetes Care* 28:956-962, 2005

2. Brands AMA, Biessels GJ, de Haan EHF, Kappelle LJ, Kessels RPC: The Effects of Type 1 Diabetes on Cognitive Performance: A meta-analysis. *Diabetes Care* 28:726-735, 2005

3. Grey M, Whittemore R, Tamborlane W: Depression in Type 1 diabetes in children: Natural history and correlates. *J Psychosom Res* 53:907-911, 2002

4. Giedd JN, Snell JW, Lange N, Rajapakse JC, Casey BJ, Kozuch PL, Vaituzis AC, Vauss YC, Hamburger SD, Kaysen D, Rapoport JL: Quantitative Magnetic Resonance Imaging of Human Brain Development: Ages 4-18. *Cereb Cortex* 6:551-559, 1996

5. King GL, Loeken MR: Hyperglycemia-induced oxidative stress in diabetic complications. *Histochem Cell Biol* 122:333-338, 2004

6. Fort PE, Losiewicz MK, Reiter CEN, Singh RSJ, Nakamura M, Abcouver SF, Barber AJ, Gardner TW: Differential Roles of Hyperglycemia and Hypoinsulinemia in Diabetes Induced Retinal Cell Death: Evidence for Retinal Insulin Resistance. *PLoS One* 6:e26498, 2011

7. Hayashi T, Faustman DL: Role of Defective Apoptosis in Type 1 Diabetes and Other Autoimmune Diseases. *Recent Prog Horm Res* 58:131-153, 2003

8. Auer RN, Siesjö BK: Hypoglycaemia: brain neurochemistry and neuropathology. *Baillieres Clin Endocrinol Metab* 7:611-625, 1993

9. Araki Y, Nomura M, Tanaka H, Yamamoto H, Tsukaguchi I, Nakamura H: MRI of the brain in diabetes mellitus. *Neuroradiology* 36:101-103, 1994

10. Ferguson SC, Blane A, Wardlaw J, Frier BM, Perros P, McCrimmon RJ, Deary IJ: Influence of an Early-Onset Age of Type 1 Diabetes on Cerebral Structure and Cognitive Function. *Diabetes Care* 28:1431-1437, 2005

11. van Elderen SGC, Brandts A, van der Grond J, Westenberg JJM, Kroft LJM, van Buchem MA, Smit JWA, de Roos A: Cerebral Perfusion and Aortic Stiffness Are Independent Predictors of White Matter Brain Atrophy in Type 1 Diabetic Patients Assessed With Magnetic Resonance Imaging. *Diabetes Care* 34:459-463, 2011

12. Musen G, Lyoo IK, Sparks CR, Weinger K, Hwang J, Ryan CM, Jimerson DC, Hennen J, Renshaw PF, Jacobson AM: Effects of Type 1 Diabetes on Gray Matter Density as Measured by Voxel-Based Morphometry. *Diabetes* 55:326-333, 2006

13. Wessels AM, Simsek S, Remijnse PL, Veltman DJ, Biessels GJ, Barkhof F, Scheltens P, Snoek FJ, Heine RJ, Rombouts SARB: Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. *Diabetologia* 49:2474-2480, 2006

14. Perantie DC, Koller JM, Weaver PM, Lugar HM, Black KJ, White NH, Hershey T: Prospectively Determined Impact of Type 1 Diabetes on Brain Volume During Development. *Diabetes* 60:3006-3014, 2011

15. Hershey T, Perantie DC, Wu J, Weaver PM, Black KJ, White NH: Hippocampal Volumes in Youth With Type 1 Diabetes. *Diabetes* 59:236-241, 2010

16. Perantie DC, Wu J, Koller JM, Lim A, Warren SL, Black KJ, Sadler M, White NH, Hershey T: Regional Brain Volume Differences Associated with Hyperglycemia and Severe Hypoglycemia in Youth with Type 1 Diabetes. *Diabetes Care* 30:2331-2337, 2007
17. Aye T, Reiss AL, Kesler S, Hoang S, Drobny J, Park Y, Schleifer K, Baumgartner H, Wilson DM, Buckingham BA: The feasibility of detecting neuropsychologic and neuroanatomic effects of type 1 diabetes in young children. *Diabetes Care* 34:1458-1462, 2011

18. Wechsler D: *Wechsler Abbreviated Scale of Intelligence (WASI)*. San Antonio, TX, The Psychological Corporation, 1999

19. Wechsler D: *Wechsler Preschool Primary Scale of Intelligence - Third Edition (WPPSI-III)*. San Antonio, TX, The Psychological Corporation, 2002

20. Wechsler D: *Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV)*. San Antonio, TX, The Psychological Corporation, 2003

21. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W: Evaluation of a New Measure of Blood Glucose Variability in Diabetes. *Diabetes Care* 29:2433-2438, 2006

22. Jack CR, Jr., Bernstein MA, Fox NC, Alexander G, Harvey D, Borowski B, Briton PJ, J LW, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, Fox-Bosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT, Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, Green R, Bartzokis G, Glover G, Mugler J, Weiner MW: The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. *J Magn Reson Imaging* 27:685-691, 2008

23. Talairach J, Tournoux P: *Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging*. New York, Thieme Medical Publishers, 1988

24. Ashburner J, Friston KJ: Unified segmentation. *NeuroImage* 26:839-851, 2005

25. Zhang Y, Brady M, Smith S: Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. *IEEE Trans Med Imaging* 20:45-57, 2001

26. Ashburner J: A fast diffeomorphic image registration algorithm. *NeuroImage* 38:95-113, 2007

27. Worsley KJ, Andermann M, Kouli T, MacDonald D, Evans AC: Detecting changes in nonisotropic images. *Hum Brain Mapp* 8:98-101, 1999

28. Stonnington CM, Tan G, Klöppel S, Chu C, Draganski B, Jack Jr CR, Chen K, Ashburner J, Frackowiak RSI: Interpreting scan data acquired from multiple scanners: A study with Alzheimer's disease. *NeuroImage* 39:1180-1185, 2008

29. Franc DT, Kodl CT, Mueller BA, Muetzel RL, Lim KO, Seaquist ER: High connectivity between reduced cortical thickness and disrupted white matter tracts in long-standing type 1 diabetes. *Diabetes* 60:315-319, 2011

30. Tiemeier H, Lenroot RK, Greenstein DK, Tran L, Pierson R, Giedd JN: Cerebellum development during childhood and adolescence: a longitudinal morphometric MRI study. *NeuroImage* 49:63-70, 2010

31. Paulin MG: The role of the cerebellum in motor control and perception. *Brain Behav Evol* 41:39-50, 1993

32. Stoodley CJ, Schmahmann JD: Functional topography in the human cerebellum: a meta-analysis of neuroimaging studies. *NeuroImage* 44:489-501, 2009

33. Taki Y, Hashizume H, Sassa Y, Takeuchi H, Asano M, Asano K, Kotozaki Y, Nouchi R, Wu K, Fukuda H, Kawashima R: Correlation among body height, intelligence, and brain gray matter volume in healthy children. *NeuroImage* 59:1023-1027, 2012

34. Lenroot RK, Giedd JN: Brain development in children and adolescents: Insights from anatomical magnetic resonance imaging. *Neurosci Biobehav Rev* 30:718-729, 2006
35. Shaw P, Greenstein D, Lerch J, Clasen L, Lenroot R, Gogtay N, Evans A, Rapoort J, Giedd J: Intellectual ability and cortical development in children and adolescents. *Nature* 440:676-679, 2006
36. Bondy CA, Cheng CM: Signaling by insulin-like growth factor 1 in brain. *Eur J Pharmacol* 490:25-31, 2004
37. Wang W-T, Lee P, Yeh H-W, Smirnova IV, Choi I-Y: Effects of acute and chronic hyperglycemia on the neurochemical profiles in the rat brain with streptozotocin-induced diabetes detected using in vivo $^1$H MR spectroscopy at 9.4 T. *J Neurochem* 121:407-417, 2012
38. Hansen SH: The role of taurine in diabetes and the development of diabetic complications. *Diabetes Metab Res Rev* 17:330-346, 2001
39. Yang C, DeVisser A, Martinez JA, Poliakov I, Rosales-Hernandez A, Ayer A, Garven A, Zaver S, Rincon N, Xu K, Tuor U, Schmidt AM, Toth C: Differential impact of diabetes and hypertension in the brain: adverse effects in white matter. *Neurobiol Dis* 42:446-458, 2011
40. Aye T, Barnea-Goraly N, Ambler C, Hoang S, Schleifer K, Park Y, Drobny J, Wilson DM, Reiss AL, Buckingham BA: White Matter Structural Differences in Young Children With Type 1 Diabetes: A Diffusion Tensor Imaging Study. *Diabetes Care* 35:2167-2173, 2012
41. Antenor-Dorsey JA, Meyer E, Rutlin J, Perantie DC, White NH, Arbelaez AM, Shimony JS, Hershey T: White matter microstructural integrity in youth with type 1 diabetes. *Diabetes* 62:581-589, 2013
42. Miyake A, Friedman NP, Emerson MJ, Witzki AH, Howarter A, Wager TD: The Unity and Diversity of Executive Functions and Their Contributions to Complex "Frontal Lobe" Tasks: A Latent Variable Analysis. *Cogn Psychol* 41:49-100, 2000
43. Craig AD: How do you feel? Interoception: the sense of the physiological condition of the body. *Nat Rev Neurosci* 3:655-666, 2002
44. Binder JR, Frost JA, Hammeke TA, Bellgowan PSF, Springer JA, Kaufman JN, Possing ET: Human Temporal Lobe Activation by Speech and Nonspeech Sounds. *Cereb Cortex* 10:512-528, 2000
45. Fang F, Lue L-F, Yan S, Xu H, Luddy JS, Chen D, Walker DG, Stern DM, Yan S, Schmidt AM, Chen JX, Yan SS: RAGE-dependent signaling in microglia contributes to neuroinflammation, $\beta$ accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. *FASEB J* 24:1043-1055, 2010
Table 1. Descriptive statistics of study cohort

|                             | T1DM         | Control     | p    |
|-----------------------------|--------------|-------------|------|
| n=210                       | 142 (66f,76m)| 68 (33f,35m)|      |
| Age                         | 7.0 ± 1.7    | 7.0 ± 1.8   | 0.94 |
| GMV (mL)†                   | 688 ± 44     | 691 ± 38    | 0.73 |
| WMV (mL)†                   | 446 ± 31     | 446 ± 28    | 0.89 |
| GMV+WMV (mL)†               | 1134 ± 72    | 1137 ± 64   | 0.79 |
| **Clinical Measures**        |              |             |      |
| T1DM Onset Age (yrs)        | 4.1 ± 1.9    | n/a         | n/a  |
| T1DM Duration (yrs)         | 2.9 ± 2.0    | n/a         | n/a  |
| HbA1c at DX (n=116)         | 10.4 ± 1.9   | n/a         | n/a  |
| HbA1c at Baseline           | 7.9 ± 0.9    | 5.2 ± 0.2   | n/a  |
| Incremental HbA1c>6.0%      | 5.8 ± 4.6    | n/a         | n/a  |
| **CGM Data**                |              |             |      |
| Hours of CGM data           | 268          | n/a         | n/a  |
| Average Mean blood glucose  | 194 ± 37     | n/a         | n/a  |
| **Cognitive Measures**       |              |             |      |
| FSIQ (z-score)              | -0.09±1.0    | 0.19±0.9    | 0.02 |

† Adjusted for Age and Sex
Table 2. VBM results table

| Model                          | Covariates               | Regions contained in cluster                                                                 | Peak voxel (x,y,z) | t-Score | Volume (voxels) | p-value* |
|-------------------------------|--------------------------|-----------------------------------------------------------------------------------------------|--------------------|---------|----------------|----------|
| **Between groups**            |                          |                                                                                              |                    |         |                |          |
| Control>T1D                   | GMV, Age, Sex            | Bilateral cerebellum, precuneus, cuneus, calcarine, lingual, fusiform                        | 14,-53,0           | 4.09    | 16788          | <0.001   |
| T1D>Control                   | GMV, Age, Sex            | Left MFG, IFG, SFG, temporal pole (STG, MTG), insula                                        | -28,40,33          | 3.91    | 9853           | 0.002    |
| **Negative glycemic correlations with brain volume for T1D** |                          |                                                                                              |                    |         |                |          |
| HbA1cAUC6%(−)                 | GMV, Age, Sex            | Bilateral lingual, fusiform, right parahippocampal, bilateral cerebellum                      | 26,-20,-27         | 3.88    | 7532           | <0.001** |
| T1DDuration(−)                | GMV, Age, Sex            | Bilateral medial orbitalfrontal, rectal gyrii, and anterior cingulate                        | -4,22,-3           | 3.98    | 7464           | 0.001**  |
| T1DDuration(−)                | Sex                      | Left anterior frontal lobe                                                                   | -21,34,-6          | 4.24    | 5158           | <0.001** |
| CGM mean glucose(−)           | GMV, Age, Sex            | Right cerebellum, vermis, fusiform, lingual, ITG                                             | 30,-81,-27         | 3.8     | 8063           | 0.007    |
| **Positive glycemic correlations with brain volume for T1D** |                          |                                                                                              |                    |         |                |          |
| HbA1cDx(+)                    | GMV, Age, Sex            | Left insula, IFG, temporal pole (STG, MTG)                                                   | -52,-5,0           | 3.67    | 7884           | 0.01     |
|                              |                          | Right insula, IFG, temporal (STG, MTG), precentral                                          | 52,10,-19          | 3.43    | 5434           | 0.054    |
| CGM mean glucose(+)           | GMV, Age, Sex            | Left IFG, insula, MFG, temporal pole (STG)                                                   | -50,43,9           | 4.53    | 6083           | 0.03     |
| **Positive IQ correlations with brain volume for controls** |                          |                                                                                              |                    |         |                |          |
| Controls-Frontal regions      | GMV, Age, Sex, ParentIQ  | Bilateral medial SFG, supplementary motor area, anterior cingulate, medial orbitofrontal gyrus, rectal gyrii | 8,46,-10           | 4.46    | 21520          | <0.001   |
| Controls-Posterior regions    | GMV, Age, Sex, ParentIQ  | Bilateral superior cerebellum, lingual, calcarine, cuneus, fusiform, left parahippocampal gyrus | 30,-41,-21         | 3.72    | 9174           | 0.007    |

* All p-values are cluster extent corrected for FWE and non-stationary smoothness

**p-value is from ROI analysis
### Table 3: Regions with Between-Group Differences and Glycemic Correlations

| Combined clusters                     | Regions contained in conjunction                                                                 | Centroid          | Volume (voxels) | Overlap* (percent) |
|--------------------------------------|---------------------------------------------------------------------------------------------------|-------------------|-----------------|--------------------|
| T1D>Control and Mean Glucose(+)      | Left insula, L anterior temporal gyrus, L dorsolateral PFC                                        | -36, 2, 3         | 1561            | 10.8               |
| T1D>Control and HbA1cDx(+)           | Left insula, L inferior frontal pars operculum and pars triangularis                              | -54, 16, 12       | 734             | 4.3                |
| Control>T1D and Mean Glucose(-)      | Right cerebellar lobes VI and crus I, vermis                                                      | 20, -80, -24      | 2061            | 9.0                |
| Control>T1D and HbA1cAUC6%(-)         | Bilateral lingual gyrii, R fusiform, bilateral cerebellum lobes VI, L cuneus                      | 18 -80, -16       | 1203            | 5.2                |

*Ratio of volume of intersection to volume of union
Table 4: Correlations of GMV with IQ in regions with both glycemic and cognitive effects

| Combined clusters | Regions contained in conjunction | Centroid | Volume (voxels) | Controls p-value | T1D p-value | Interaction |
|-------------------|----------------------------------|----------|----------------|-----------------|-------------|-------------|
| IQ and Duration   | Bilateral medial orbitofrontal gyrus and dorsal anterior cingulate | -6, 38, -8 | 2919 | 0.007 ($r=0.28$) | 0.014 ($r=0.10$) | 0.13 |
| IQ and Mean Glucose(-) | Bilateral superior cerebellum, vermis, R fusiform, R lingual | 18, -80, -24 | 2838 | 0.015 ($r=0.33$) | n.s., ($r=0.09$) | 0.18 |
| IQ and HbA1cAUC6% | Right fusiform, lingual, cerebellar lobes VI and crus I | 26, -20, -27 | 1255 | <0.001 ($r=0.30$) | n.s., ($r=0.01$) | <0.001 |
| IQ and C>D | Bilateral cerebellar lobes VI, vermis, R crus I, R lingual, R cuneus | 12, -76, -21 | 4326 | 0.005 ($r=0.33$) | n.s., ($r=0.03$) | 0.03 |

$r$ = standardized regression coefficient of GMV with IQ
All interaction results covaried by GMV, group, age, and sex.
Figure Legends

Figure 1: Sagittal (left) and axial (right) 3-dimensional renderings of clusters of significant differences between T1D and controls. Increased GMV in lateral temporo-frontal regions in T1D relative to controls (red cluster, \( p<0.01 \)) was also found to be associated with higher HbA\(_{1C}D_X\). Decreased GMV in occipital regions and cerebellum in T1D relative to controls (yellow cluster, \( p<0.001 \)) was found to be associated with higher HbA\(_{1C}AUC6\%\) and higher mean glucose.

Figure 2: Significant GMV clusters from whole brain regression analysis of glycemic measures in the T1D group (height threshold of \( T=1.66 \), cluster extent threshold of \( p<0.05 \) and corrected for FWE and non-stationary smoothness). Clusters are overlaid on the average GM template. HbA\(_{1C}AUC6\%\)\((-\) \( p<0.001 \), T1DDuration\((-\), GMV \( p=0.001 \), T1DDuration\((-\), WMV \( p<0.001 \), HbA\(_{1C}D_x\)\((+\) \( p=0.01 \), meanBG\((-\) \( p=0.007 \) and meanBG\((+\) \( p=0.03 \).

Figure 3: Regions with significant correlations between IQ and GMV. (Top) Clusters from whole brain regression analysis of IQ in the control group (height threshold of \( T=1.66 \), cluster extent threshold of \( p<0.05 \) and corrected for FWE and non-stationary smoothness). (Bottom) Conjunction regions with IQ-GMV correlations in controls and glycemic-GMV correlations in T1D. Color denotes glycemic variable/contrast: T1DDuration\((-\) (blue), mean glucose\((-\) (green), control>T1D (red), overlap (yellow). Clusters are overlaid on the average GM template.
Sagittal (left) and axial (right) 3-dimensional renderings of clusters of significant differences between T1D and controls. Increased GMV in lateral temporo-frontal regions in T1D relative to controls (red cluster, $p<0.01$) was also found to be associated with higher HbA$_{1c}$D$_X$. Decreased GMV in occipital regions and cerebellum in T1D relative to controls (yellow cluster, $p<0.001$) was found to be associated with higher HbA$_{1c}$AUC$_{6%}$ and higher mean glucose.

55x34mm (300 x 300 DPI)
Significant GMV clusters from whole brain regression analysis of glycemic measures in the T1D group (height threshold of $T=1.66$, cluster extent threshold of $p<0.05$ and corrected for FWE and non-stationary smoothness). Clusters are overlaid on the average GM template. HbA$_1c$AUC$_{6%}(-)$ ($p<0.001$), T1DDuration(-, GMV) ($p=0.001$), T1DDuration(-, WMV) ($p<0.001$), HbA$_1c$Dx(+) ($p=0.01$), meanBG(-) ($p=0.007$) and meanBG(+) ($p=0.03$).

179x177mm (300 x 300 DPI)
Regions with significant correlations between IQ and GMV. (Top) Clusters from whole brain regression analysis of IQ in the control group (height threshold of $T=1.66$, cluster extent threshold of $p<0.05$ and corrected for FWE and non-stationary smoothness). (Bottom) Conjunction regions with IQ-GMV correlations in controls and glycemic-GMV correlations in T1D. Color denotes glycemic variable/contrast: T1DDuration(-) (blue), mean glucose(-) (green), control>T1D (red), overlap (yellow). Clusters are overlaid on the average GM template.

72x28mm (300 x 300 DPI)